Confused and disoriented pets? Dementia is not just for humans
Sometimes the little guy just stops and doesn't know where he is any more. At 15 years old, Olli the pug is very old, in need of help, often disoriented. He doesn't hear or see much and his hind legs hurt.
"Olli has had dementia for a few years," says owner Ute Hausmann. She has completely adjusted to his needs, caring for, nurturing, looking after and encouraging the animal that has been living with her and her husband in the Rheinisch-Bergisch district near Cologne for 11 years. Because: "Olli is dearly loved."
Dementia widespread among older dogs and cats
According to Holger Volk, a doctor at the University of Veterinary Medicine Hanover, dementia is common among dogs and cats of an advanced age.
He says that about one in three dogs aged 12 to 13 years show clinical symptoms.
By the age of 15 to 16, two out of three dogs are affected by "canine cognitive dysfunction syndrome."
And among very old cats at about 16 years of age, around 50% have dementia, known as "feline" syndrome. So, all in all, a "huge number," he says.
Early intervention is very important. "When pet owners notice abnormalities, it is often almost too late," says Volk, who heads the hospital for small animals.
The disease is difficult to diagnose because the signs vary and dementia develops progressively. It is usually accompanied by other illnesses and not easily separated from "normal" degenerative signs of old age.
What causes dementia and what to watch for?
Changes in an animal's brain metabolism, inflammation and protein deposits all cause nerve cells to no longer work properly. Those changes make an animal slow down and some forget practised commands. They may get confused and no longer sleep well – and there are also behavioural changes.
"Loner behaviour and withdrawal" are examples Volk cites. Joint pain and dental disease are common.
Prevention can help. Measures can include a suitable low-sugar diet – with certain fatty acids that work as energy sources for older animals and prevent inflammatory reactions.
If dementia is diagnosed, special food is definitely part of a treatment strategy. Exercise and mental stimulation are also key.
"There are not many medications available" – except for a stimulant to help with persistent poor sleep or a means to promote blood circulation, says Volk.
So it is important to observe your animal carefully for any changes.
Cats: Harder to watch closely
Cats like to do their own thing – and therefore tend to slip under the radar and out of sight. But signs of dementia in cats can include appearing anxious, becoming less active and interacting less, the veterinarian says.
It is also very common for cats to meow loudly, almost scream at night, a sign the animal is trying to locate itself.
A cat may also struggle to find its litter tray – just as a normally house-trained dog may stop indicating when it has to go and instead relieve itself in the home, according to the animal welfare foundation Four Paws.
Dementia brings changes not only for the affected animals, but also for their families. But with patience and the right care, the progression of the incurable disease can be slowed down.
As for the senior pug Olli, exercise and a routine are very important. Owner Hausmann massages her pug's aching hind legs every morning. Then she takes him out two to three times a day – always the same familiar short distances and very slowly.
"It helps him to cope," she says.
Even a curb can pose a challenge. After the short walk, the 74-year-old lifts the 9-kilogram bundle onto the sofa at home. "Olli used to be very boisterous and lively. Now he's slow, unsure of himself and always wants to be where I am, constantly following me around."
Engaging with other four-legged friends is out of the question.
"He doesn't want anything to do with other dogs any more. He used to be in a good mood, was very interested in females, but now he doesn't like any contact at all."
At night, her pug often wakes up and seems completely lost. "Olli has a cautious, gentle character, he's not aggressive and luckily he still goes to the toilet outside," says Hausmann.
He manages to make himself noticed – and then he's out the front door and into the garden.
Hausmann, a former nursery school teacher who knows her pug inside out, doesn't miss a beat. Converted into human years, Olli is almost 100 years old.
Growing awareness of older animals' needs
Veterinarian Volk has observed that many pets are now living to a ripe old age, and this has led to a growing awareness of the issue.
However, he says doctors often only diagnose and treat concomitant diseases such as heart, kidney or joint problems. "The brain is not the focus of attention, but it is becoming more and more so."
He knows that it often helps pet owners when they receive clarity and a confirmed diagnosis of dementia.
Similar to humans, the same applies to dogs and cats: Age is a risk factor, but not a cause of dementia, he says. "We need to work much harder on prevention. A happy life includes a healthy brain."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
6 hours ago
- Medscape
Two-Step Approach Cuts HFpEF Diagnostic Complexity
Assessing left atrial volume and natriuretic peptides (LA/NP) can identify heart failure with preserved ejection fraction (HFpEF) with an 88% specificity and 97% positive predictive value. The strategy reduces the need for additional diagnostics by decreasing intermediate Heart Failure Association pre-test assessment, echocardiography & natriuretic peptide, functional testing, final etiology (HFA-PEFF) or H₂FPEF (Heavy, two or more hypertensive drugs, atrial fibrillation, pulmonary hypertension, elder age > 60 years, elevated filling pressures) algorithm scores by 27%-56%. METHODOLOGY: Researchers developed the diagnostic approach to rule in HFpEF using LA indexed for height 2 (LAViH 2 ; cut-off above 35.5 mL/m 2 in sinus rhythm or above 38.6 mL/m 2 in atrial fibrillation) and natriuretic peptides (as per the HFA-PEFF major criterion) with data from 443 patients with suspected HFpEF and validated in two independent cohorts. (LAViH ; cut-off above 35.5 mL/m in sinus rhythm or above 38.6 mL/m in atrial fibrillation) and natriuretic peptides (as per the HFA-PEFF major criterion) with data from 443 patients with suspected HFpEF and validated in two independent cohorts. End-systolic LA was manually traced in echocardiographic apical four- and two-chamber views and indexed for both body surface area and height 2 , with height 2 -indexed values showing better diagnostic performance in patients with obesity. , with height -indexed values showing better diagnostic performance in patients with obesity. Researchers developed the simplified approach by determining abnormal values for each measure of LA based on the highest value in control individuals, stratified by sinus rhythm/atrial fibrillation, and using elevated natriuretic peptides based on the HFA-PEFF major criterion. TAKEAWAY: The LA/NP approach identified 60% of HFpEF patients with an 88% specificity and a 97% positive predictive value in the derivation cohort, with similar results in the validation cohorts (76%-80% specificity, 92%-97% positive predictive value). The validation cohorts confirmed the LA/NP approach, with a 21%-57% reduction in intermediate scores, demonstrating consistent diagnostic accuracy across different clinical HFpEF profiles. Replacing LAViH2 with LA reservoir strain showed comparable results, suggesting flexibility in the echocardiographic parameters that can be used in this simplified diagnostic approach. IN PRACTICE: 'Using the LA/NP approach as a first step in patients suspected for HfpEF before using the HFA-PEFF or H 2 FPEF algorithm as a second step may substantially reduce the need for additional diagnostics to diagnose HfpEF,' the researchers wrote. SOURCE: The study was led by Jerremy Weerts, MSc, MD, of Maastricht University Medical Center in Maastricht, the Netherlands. It was published online in European Journal of Heart Failure and presented at the Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025 meeting. LIMITATIONS: The analyses were performed retrospectively in three independent, prospective cohorts from university hospitals, each with a high prevalence of diagnosed HFpEF, which may affect the performance of the LA/NP approach in less selected populations. The use of different natriuretic peptide assays across cohorts limited the derivation of new cut-off values for the LA/NP approach. Right heart catheterization was not performed in all patients, although this reflects daily clinical practice and aligns with large clinical trials in HFpEF. DISCLOSURES: Weerts reported receiving grants from Corvia Medical, CSL Vifor, and Boehringer Ingelheim, unrelated to the submitted work. The study was supported by the Dutch Heart Foundation (grant numbers CVON2017-21-SHE PREDICTS HF and CVON2015-10-Early HFpEF) and the Health Foundation Limburg. Additional disclosures are noted in the original article.


Medscape
8 hours ago
- Medscape
SGLT2 Inhibitors Linked to Lower Risk for AF in T2D
The use of SGLT2 inhibitors was associated with a reduced risk for atrial fibrillation (AF) in patients with type 2 diabetes (T2D). METHODOLOGY: SGLT2 inhibitors have been shown to provide therapeutic benefits to patients with heart failure and AF; however, data on their protective effect on AF in patients without heart failure are inconsistent. Researchers conducted a retrospective case-control study in Germany to assess the association between the use of various antihyperglycemic medications between 2005 and 2023 and the diagnosis of AF in patients with T2D during the same period. They used data from the Disease Analyzer database including 29,424 patients with T2D aged 40 years or older with an initial diagnosis of AF who were matched to an equal number of control patients without AF (mean age at the index date , 76 years; 46%-47% women; average diabetes duration prior to the index date for both cohorts, 6.8 years). Antihyperglycemic therapies included metformin, sulfonylurea, GLP-1 receptor agonists (RAs), DPP-4 inhibitors, SGLT2 inhibitors, and insulin. TAKEAWAY: Treatment with SGLT2 inhibitors was associated with a reduced risk for AF (odds ratio [OR], 0.82; P < .01 per year of therapy). < .01 per year of therapy). GLP-1 RAs were associated with a slightly reduced risk for AF (OR, 0.93; P < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; P < .01 for all). < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; < .01 for all). The use of sulfonylurea was linked to a slightly increased risk for AF (OR, 1.09; P < .01), with the strongest association among patients younger than 70 years (OR, 1.18; P < .01). < .01), with the strongest association among patients younger than 70 years (OR, 1.18; < .01). Patients with AF began SGLT2 inhibitor therapy on average 2.6 years before diagnosis, with the therapy lasting an average of 2.3 years. IN PRACTICE: 'SGLT2i [inhibitors] and GLP-1 RA may provide an important, heretofore unknown effect of antidiabetic therapy: The prevention of AF, a cardiac condition of massive prevalence and severe impact for those affected,' the authors wrote. SOURCE: This study was led by Mark Luedde, MD, and Jamschid Sedighi, MD, of the University Hospital of Giessen and Marburg, Giessen, Germany. It was published online on June 03, 2025, in Diabetes, Obesity and Metabolism . LIMITATIONS: This study lacked data on the frequency and duration of AF episodes. The absence of data on cardiovascular disease severity may have affected the balance between groups. Potential bias due to the indication of oral antidiabetic treatments cannot be ruled out. DISCLOSURES: This study did not report any specific funding. The authors reported having no relevant conflicts of interest.
Yahoo
10 hours ago
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data